These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
728 related articles for article (PubMed ID: 11593409)
41. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Jücker M; Südel K; Horn S; Sickel M; Wegner W; Fiedler W; Feldman RA Leukemia; 2002 May; 16(5):894-901. PubMed ID: 11986952 [TBL] [Abstract][Full Text] [Related]
42. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Toulany M; Baumann M; Rodemann HP Mol Cancer Res; 2007 Aug; 5(8):863-72. PubMed ID: 17699110 [TBL] [Abstract][Full Text] [Related]
43. Both SH2 domains are involved in interaction of SHP-1 with the epidermal growth factor receptor but cannot confer receptor-directed activity to SHP-1/SHP-2 chimera. Tenev T; Keilhack H; Tomic S; Stoyanov B; Stein-Gerlach M; Lammers R; Krivtsov AV; Ullrich A; Böhmer FD J Biol Chem; 1997 Feb; 272(9):5966-73. PubMed ID: 9038217 [TBL] [Abstract][Full Text] [Related]
44. p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Zhang S; Broxmeyer HE Biochem Biophys Res Commun; 1999 Jan; 254(2):440-5. PubMed ID: 9918857 [TBL] [Abstract][Full Text] [Related]
45. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Cui TX; Nakagami H; Nahmias C; Shiuchi T; Takeda-Matsubara Y; Li JM; Wu L; Iwai M; Horiuchi M Mol Endocrinol; 2002 Sep; 16(9):2113-23. PubMed ID: 12198247 [TBL] [Abstract][Full Text] [Related]
46. Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction. Li C; Friedman JM Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9677-82. PubMed ID: 10449753 [TBL] [Abstract][Full Text] [Related]
47. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma. Staverosky JA; Muldoon LL; Guo S; Evans AJ; Neuwelt EA; Clinton GM Clin Cancer Res; 2005 Jan; 11(1):335-40. PubMed ID: 15671564 [TBL] [Abstract][Full Text] [Related]
48. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Klinghoffer RA; Duckworth B; Valius M; Cantley L; Kazlauskas A Mol Cell Biol; 1996 Oct; 16(10):5905-14. PubMed ID: 8816504 [TBL] [Abstract][Full Text] [Related]
49. Positive regulation of c-Jun N-terminal kinase and TNF-alpha production but not histamine release by SHP-1 in RBL-2H3 mast cells. Xie ZH; Zhang J; Siraganian RP J Immunol; 2000 Feb; 164(3):1521-8. PubMed ID: 10640770 [TBL] [Abstract][Full Text] [Related]
50. The phosphotyrosine phosphatase SHP-2 participates in a multimeric signaling complex and regulates T cell receptor (TCR) coupling to the Ras/mitogen-activated protein kinase (MAPK) pathway in Jurkat T cells. Frearson JA; Alexander DR J Exp Med; 1998 May; 187(9):1417-26. PubMed ID: 9565634 [TBL] [Abstract][Full Text] [Related]
51. Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling. Kim SO; Jiang J; Yi W; Feng GS; Frank SJ J Biol Chem; 1998 Jan; 273(4):2344-54. PubMed ID: 9442080 [TBL] [Abstract][Full Text] [Related]
52. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain. Hofmann BT; Jücker M Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814 [TBL] [Abstract][Full Text] [Related]
53. Encapsulated Streptococcus suis inhibits activation of signaling pathways involved in phagocytosis. Segura M; Gottschalk M; Olivier M Infect Immun; 2004 Sep; 72(9):5322-30. PubMed ID: 15322029 [TBL] [Abstract][Full Text] [Related]
54. A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation. Deb TB; Wong L; Salomon DS; Zhou G; Dixon JE; Gutkind JS; Thompson SA; Johnson GR J Biol Chem; 1998 Jul; 273(27):16643-6. PubMed ID: 9642214 [TBL] [Abstract][Full Text] [Related]
55. Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation. Dustin LB; Plas DR; Wong J; Hu YT; Soto C; Chan AC; Thomas ML J Immunol; 1999 Mar; 162(5):2717-24. PubMed ID: 10072516 [TBL] [Abstract][Full Text] [Related]
56. The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. Kolli S; Zito CI; Mossink MH; Wiemer EA; Bennett AM J Biol Chem; 2004 Jul; 279(28):29374-85. PubMed ID: 15133037 [TBL] [Abstract][Full Text] [Related]
58. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen). Band CJ; Posner BI; Dumas V; Contreres JO Mol Endocrinol; 1997 Dec; 11(13):1899-910. PubMed ID: 9415395 [TBL] [Abstract][Full Text] [Related]
59. S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). Baudhuin LM; Jiang Y; Zaslavsky A; Ishii I; Chun J; Xu Y FASEB J; 2004 Feb; 18(2):341-3. PubMed ID: 14657000 [TBL] [Abstract][Full Text] [Related]
60. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Qu CK; Shi ZQ; Shen R; Tsai FY; Orkin SH; Feng GS Mol Cell Biol; 1997 Sep; 17(9):5499-507. PubMed ID: 9271425 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]